Spry1 as a potential new hypoxia modulator in cutaneous melanoma

被引：0
|
作者：
Montico, Barbara
Giurato, Giorgio
Guerrieri, Roberto
Salvati, Annamaria
Colizzi, Francesca
Baboci, Lorena
Sigalotti, Luca
Covre, Alessia
Maio, Michele
Steffan, Agostino
Nyman, Tuula A.
Weisz, Alessandro
Mongiat, Maurizio
Andreuzzi, Eva
Fratta, Elisabetta
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-4806
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4806
引用
收藏
页数：3
相关论文
共 50 条
  • [1] SPRY1 is a candidate oncogene in braf-mutant cutaneous melanoma
    Montico, B.
    Giurato, G.
    Colizzi, F.
    Comaro, E.
    Pivetta, E.
    Benedetti, D.
    Weisz, A.
    Steffan, A.
    Sigalotti, L.
    Fratta, E.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E115 - E116
  • [2] Spry1 targeting enhances E-cadherin expression in cutaneous melanoma
    Montico, Barbara
    Giurato, Giorgio
    Guerrieri, Roberto
    Salvati, Annamaria
    Colizzi, Francesca
    Baboci, Lorena
    Sigalotti, Luca
    Covre, Alessia
    Maio, Michele
    Steffan, Agostino
    Nyman, Tuula Anneli
    Weisz, Alessandro
    Mongiat, Maurizio
    Andreuzzi, Eva
    Fratta, Elisabetta
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Suppression of Spry1 sensitizes cutaneous melanoma to BRAF-targeted therapy
    Giurato, Giorgio
    Colizzi, Francesca
    Rizzo, Aurora
    Martorelli, Debora
    Montico, Barbara
    Mastorci, Katy
    Benedetti, Dania
    Weisz, Alessandro
    Dolcetti, Riccardo
    Luca, Sigalotti
    Fratta, Elisabetta
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
    Montico, Barbara
    Giurato, Giorgio
    Guerrieri, Roberto
    Colizzi, Francesca
    Salvati, Annamaria
    Nassa, Giovanni
    Lamberti, Jessica
    Memoli, Domenico
    Sabatelli, Patrizia
    Comelli, Marina
    Bellazzo, Arianna
    Fejza, Albina
    Camicia, Lucrezia
    Baboci, Lorena
    Dal Bo, Michele
    Covre, Alessia
    Nyman, Tuula A.
    Weisz, Alessandro
    Steffan, Agostino
    Maio, Michele
    Sigalotti, Luca
    Mongiat, Maurizio
    Andreuzzi, Eva
    Fratta, Elisabetta
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2025, 44 (01)
  • [5] Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy
    Barbara Montico
    Francesca Colizzi
    Giorgio Giurato
    Aurora Rizzo
    Annamaria Salvati
    Lorena Baboci
    Dania Benedetti
    Eliana Pivetta
    Alessia Covre
    Michele Dal Bo
    Alessandro Weisz
    Agostino Steffan
    Michele Maio
    Luca Sigalotti
    Elisabetta Fratta
    Cell Death & Disease, 11
  • [6] Spry1 silencing reduces HIF1α-induced glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
    Montico, B.
    Giurato, G.
    Guerrieri, R.
    Colizzi, F.
    Salvati, A.
    Nassa, G.
    Lamberti, J.
    Sabatelli, P.
    Comelli, M.
    Bellazzo, A.
    Camicia, L.
    Baboci, L.
    Nyman, T.
    Weisz, A.
    Steffan, A.
    Sigalotti, L.
    Mongiat, M.
    Andreuzzi, E.
    Fratta, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S103 - S104
  • [7] Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy
    Montico, Barbara
    Colizzi, Francesca
    Giurato, Giorgio
    Rizzo, Aurora
    Salvati, Annamaria
    Baboci, Lorena
    Benedetti, Dania
    Pivetta, Eliana
    Covre, Alessia
    Dal Bo, Michele
    Weisz, Alessandro
    Steffan, Agostino
    Maio, Michele
    Sigalotti, Luca
    Fratta, Elisabetta
    CANCER RESEARCH, 2020, 80 (16)
  • [8] Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy
    Montico, Barbara
    Colizzi, Francesca
    Giurato, Giorgio
    Rizzo, Aurora
    Salvati, Annamaria
    Baboci, Lorena
    Benedetti, Dania
    Pivetta, Eliana
    Covre, Alessia
    dal Bo, Michele
    Weisz, Alessandro
    Steffan, Agostino
    Maio, Michele
    Sigalotti, Luca
    Fratta, Elisabetta
    CELL DEATH & DISEASE, 2020, 11 (05)
  • [9] Tumor-specifically hypoxia-induced therapy of SPRY1/2 displayed differential therapeutic efficacy for melanoma
    Liu, Zhipeng
    Liu, Xiufeng
    Cao, Wenmin
    Hua, Zi-Chun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (02): : 792 - 801
  • [10] Spry1 and Spry2 are necessary for eyelid closure
    Kuracha, Murali R.
    Siefker, Ed
    Licht, Jonathan D.
    Govindarajan, Venkatesh
    DEVELOPMENTAL BIOLOGY, 2013, 383 (02) : 227 - 238
12345